2,4,7,9-tetramethyldec-5-yne-4,7-diol

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

migrated information: read-across based on grouping of substances (category approach)

Adequacy of study:

key study

Study period:

2004

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: according to EC Directive 92/69/EEC and Regulation EC/440/2008 guideline methods under GLP conditions. This data valid as documented CCRF for this category (Acetylenic geminalic diols)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2004

Report date:

2004

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)

Deviations:

no

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

17913-76-7

EC Number:

605-849-6

Cas Number:

17913-76-7

IUPAC Name:

17913-76-7

Constituent 2

Reference substance name:

2,4,7,9-Tetramethyl-4,7-diol

IUPAC Name:

2,4,7,9-Tetramethyl-4,7-diol

Constituent 3

Reference substance name:

451-160-7

EC Number:

451-160-7

IUPAC Name:

451-160-7

Details on test material:

Purity: 98.3 %
Lot Number: 12671

Test animals

Species:

rat

Strain:

other: HsdBrlHan:WIST

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on analytical verification of doses or concentrations:

The test article was weighed into pre-labelled beakers and
the requested volume of vehicle was measured using
suitable apparatus. The formulation was made up to volume
in a beaker or formulation bottle up to a calibrated line. The
formulation was placed on a Silverson to ensure
homogeneity, then divided into the requested number of
aliquots. A correction of 1.099 was used.

Duration of treatment / exposure:

Oral gavage. Daily for 30 days. Dose volume 5 mL/kg.

Frequency of treatment:

Daily

Doses / concentrations

Remarks:

Doses / Concentrations:
5 mL/kg
Basis:
actual ingested

No. of animals per sex per dose:

5

Control animals:

yes

Examinations

Observations and examinations performed and frequency:

Clinical Observations Twice daily (am/pm) for routine health checks and daily for
signs of ill health or overt toxicity.
Physical Examinations Weekly intervals
Body Weights Before treatment on first day of dosing, at weekly intervals
and before necropsy.
Food Consumption Weekly intervals. Calculated as g/animal/week.
Haematology All main study animals at the end of Week 4 from the
lateral caudal vein after an overnight period without food.
Clinical Chemistry# All main study animals at the end of Week 4 from the
lateral caudal vein after an overnight period without food.
In addition, blood samples were obtained from females only
in Groups 1 and 2 at necropsy from the abdominal aorta.
Functional
Observational Battery
All main study animals before initiation of treatment and
once weekly thereafter.
Observational measurements were evaluated before and
upon removal from the home cage. The animal was also
placed into a circular arena for two minutes.
In Week 4, an assessment of sensory reactivity to stimuli,
grip strength and motor activity was performed.

Sacrifice and pathology:

Necropsy All main study animals after an overnight period without
food.
Organ weights Specified organs were dissected free from fat and other
contiguous tissue and weighed before fixation.
Tissue Preservation Specified tissues were preserved in the appropriate
fixative/s
Histology Gross lesions and specified tissues from all control and high
dose main study animals.
Liver, thyroid and stomach from low and intermediate dose
animals were processed to slide stage.
Kidney from low and intermediate dose male animals were
processed to slide stage

Results and discussion

Effect levels

Dose descriptor:

NOAEL

Effect level:

ca. 150 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: overall effects

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

EnviroGem AD01 Surfactant was orally administered at dose levels of 0, 15, 150 and
1000 mg/kg/day for at least 28 days and was well tolerated. There were no significant
clinical observations, and only minor increases in bodyweight and food consumption
at 1000 mg/kg/day. Increases in total cholesterol, globulin and total protein were of
unknown toxicological significance. Microscopic changes in the liver, thyroid, male
kidney and stomach were due to effects of the test article, but only those in the liver
and thyroid were of toxicological significance. Microscopic findings in the liver,
thyroid, male kidney and stomach of animals dosed at 15 mg/kg/day were similar to
controls.

The liver weight changes and the severity of the microscopic changes in the liver,
thyroid and kidney can be associated with the increased metabolism of EnviroGem
AD01 Surfactant, and therefore, 150 mg/kg/day was considered to be The
No-Adverse-Effect Level (NOAEL).

Executive summary:

The No-Observed-Adverse-Effect-Level (NOAEL) for EnviroGem AD01 Surfactant when administered to rats by oral gavage for 28-days is 150 mg/kg/day. Toxicologically significant effects were seen in the liver and thyroid of rats dosed at 1000 mg/kg/day. The purpose of this study was to determine the toxicity of the test article, EnviroGem AD01 Surfactant, following oral (gavage) administration to the rat for at least 28 days. Male and female HsdBrIHan:WIST rats were assigned to four groups (five animals/sex/group). Each group received dose preparations at dose levels of 0, 15, 150 or 1000 mg/kg of body weight at a dose volume of 5 mL/kg. A pilot study run before the start of the study confirmed that in three male and three female rats dosed at 1000 mg/kg for five days no severe toxicity was seen. Assessment of toxicity, was based on mortality, clinical observations, clinical and anatomic pathology evaluations, clinical pathology and functional observational battery and locomotor activity. There were no decedents during the study. Total cholesterol was seen to increase in a dose-related manner in both males and females. Animals dosed at 1000 mg/kg/day recorded increases in total cholesterol compared to control of 71% for males (p<0.001) and 63% for females (p<0.01). Animals dosed at 150 mg/kg/day also showed increases in both sexes (males 29% and females 25%). A dose-related increase in globulin was seen in males dosed at 150 mg/kg/day (8%) and 1000 mg/kg/day (25%, p<0.01). Group mean globulin was also increased in a dose-related manner in females. This was reflected in an increase in total protein values in these animals. Group mean liver weights adjusted to overall mean body weight increased in males and females dosed at 150 mg/kg/day and a greater magnitude in animals dosed at 1000 mg/kg/day. Macroscopically, there was large or mottled liver, and pale or mottled kidney in some treated animals. Microscopically, in high dose animals, there was hepatocyte hypertrophy in the liver; increased follicular cell hypertrophy in the thyroid; increased hyaline droplets (males only) and focal nephropathy in the kidney; and minor squamous cell hyperplasia in the fore stomach, due to effects of the test article. Liver hepatocyte hypertrophy and increased hyaline droplets in the male kidney were also seen in intermediate dose animals. Microscopic findings in the liver, thyroid, male kidney and stomach of low dose animals were similar to controls and therefore this dose was considered to be the overall no observable effect level (NOEL). In conclusion, EnviroGem AD01 Surfactant was orally administered at dose levels of 0, 15, 150 and 1000 mg/kg/day for at least 28 days and was well tolerated. There were no significant clinical observations, and only minor increases in body weight and food consumption at 1000 mg/kg/day. Increases in total cholesterol, globulin and total protein were of unknown toxicological significance. Microscopic changes in the liver, thyroid, male kidney and stomach were due to effects of the test article, but only those in the liver and thyroid were of toxicological significance. Microscopic findings in the liver, thyroid, male kidney and stomach of animals dosed at 15 mg/kg/day were similar to controls. The liver weight changes and the severity of the microscopic changes in the liver, thyroid and kidney can be associated with the increased metabolism of EnviroGem AD01 Surfactant, and therefore, 150 mg/kg/day was considered to be The No-Observed-Adverse-Effect Level (NOAEL).